Claudia Hernández-Jiménez, Matilde Baltazares-Lipp, J. R. Olmos-Zúñiga, M. Gaxiola-Gaxiola, A. E. Guzmán-Cedillo, María T. Silva-Martínez, Rogelio Jasso-Victoria
agu-ABSTRACT. Introduction: Acute respiratory distress syndrome (ARDS) in the endothelium causes vasoconstriction, adhesion of inflammatory cells and development of pulmonary edema, pulmonary hypertension and thrombosis. This endothelial damage lowers the production of nitric oxide (NO) and increases the expression of endothelin-1 (ET-1). The aim of this study was to evaluate the effect of pretreatment with L-arginine in OA-induced ALI. Material and methods: Hemodynamic, gasometric, microscopic, immunohistochemical and plasma concentration of ET-1 and ET-1 y ETB were analyzed in an experimental model of AO-induced ARDS. The dogs were divided into three study groups: I (n = 6), control; II (n = 6), OA-induced ARDS at an IV dose of 0.09 mL/kg, untreated, and III (n = 6), pretreatment with L-arginine at 0.125 g/min/IV in 250 mL of 0.09% saline and OA-induced ARDS. Results: The hemodynamic, blood gas and gravimetric findings revealed that groups II and III developed ARDS. Intrapulmonary shunt increased in groups II and III (p < 0.05, ANDEVA Dunnett). PaO 2 /FiO 2 decreased in groups II and III with a significant difference with group I (p < 0.05, ANDEVA MR Dunnett). in an experimental model of AO-induced acute SIRA attenuated hypoxic pulmonary vasoconstriction (HPV) leading to deterioration in intrapulmonary shunting. However, the edema and inflammatory infiltrate in the tissue decreased, therefore, in this model you can only consider a potential attenuating effect on lung inflammation during the acute phase by L-arginine.
{"title":"Efecto del pretratamiento con L-arginina en un modelo experimental de síndrome de insuficiencia respiratoria aguda inducido por ácido oleico","authors":"Claudia Hernández-Jiménez, Matilde Baltazares-Lipp, J. R. Olmos-Zúñiga, M. Gaxiola-Gaxiola, A. E. Guzmán-Cedillo, María T. Silva-Martínez, Rogelio Jasso-Victoria","doi":"10.35366/97966","DOIUrl":"https://doi.org/10.35366/97966","url":null,"abstract":"agu-ABSTRACT. Introduction: Acute respiratory distress syndrome (ARDS) in the endothelium causes vasoconstriction, adhesion of inflammatory cells and development of pulmonary edema, pulmonary hypertension and thrombosis. This endothelial damage lowers the production of nitric oxide (NO) and increases the expression of endothelin-1 (ET-1). The aim of this study was to evaluate the effect of pretreatment with L-arginine in OA-induced ALI. Material and methods: Hemodynamic, gasometric, microscopic, immunohistochemical and plasma concentration of ET-1 and ET-1 y ETB were analyzed in an experimental model of AO-induced ARDS. The dogs were divided into three study groups: I (n = 6), control; II (n = 6), OA-induced ARDS at an IV dose of 0.09 mL/kg, untreated, and III (n = 6), pretreatment with L-arginine at 0.125 g/min/IV in 250 mL of 0.09% saline and OA-induced ARDS. Results: The hemodynamic, blood gas and gravimetric findings revealed that groups II and III developed ARDS. Intrapulmonary shunt increased in groups II and III (p < 0.05, ANDEVA Dunnett). PaO 2 /FiO 2 decreased in groups II and III with a significant difference with group I (p < 0.05, ANDEVA MR Dunnett). in an experimental model of AO-induced acute SIRA attenuated hypoxic pulmonary vasoconstriction (HPV) leading to deterioration in intrapulmonary shunting. However, the edema and inflammatory infiltrate in the tissue decreased, therefore, in this model you can only consider a potential attenuating effect on lung inflammation during the acute phase by L-arginine.","PeriodicalId":246416,"journal":{"name":"NCT Neumología y Cirugía de Tórax","volume":"60 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133068313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rogelio Flores-Acosta, Miroslava Félix-Ponce, Alejandra Isabel Jiménez-Gracia, Rafael Laniado-Laborín
{"title":"Coccidioidomicosis y aspergilosis en un paciente con secuelas por tuberculosis pulmonar","authors":"Rogelio Flores-Acosta, Miroslava Félix-Ponce, Alejandra Isabel Jiménez-Gracia, Rafael Laniado-Laborín","doi":"10.35366/108502","DOIUrl":"https://doi.org/10.35366/108502","url":null,"abstract":"","PeriodicalId":246416,"journal":{"name":"NCT Neumología y Cirugía de Tórax","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133242772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hidalgo – Tobon, García-Campos, Morón-Mendoza, Jiménez-Correa, Gutiérrez-Escobar, J. Azpiroz-Leehan, Santana-Miranda, J. Escobar-Alvarado, J. Sandoval-Zárate
s of the XII National Meeting of Sleep Medicine Costos del insomnio crónico asociado a trastornos anímicos: un estudio observacional en México GI Torres-Granados,* JM Martínez-Núñez,* A Barrera-Medina,‡ C Cruz-Cruz,* U Jiménez-Correa,‡ L Carvalho-Silva,* F López-Naranjo,* R Santana-Miranda‡ *Departamento de Sistemas Biológicos, UAM Xochimilco; ‡Clínica de Trastornos del Sueño, UNAM. Introducción: Los costos relacionados con el insomnio asociado a trastornos del estado de ánimo siguen siendo poco estudiados pese a su alta prevalencia e incidencia mundial asociada a la pandemia COVID-19. Objetivos: Determinar los costos directos e indirectos del insomnio asociado a trastorno anímico. Material y métodos: Estudio observacional prospectivo, incluyó pacientes entre 18 y 65 años, diagnosticados con insomnio crónico asociado a trastornos del estado de ánimo (depresión y/o ansiedad) entre febrero de 2019 y febrero de 2020. Los datos sobre utilización de recursos sanitarios se recopilaron mediante la revisión de los registros médicos. Se diseñó un cuestionario para evaluar los costos no médicos directos e indirectos con datos sociodemográficos, transporte, bebidas energéticas, gastos en actividad física, modificaciones del hogar, compra de accesorios especiales, jornada laboral y salario. El ausentismo y el presentismo laboral se determinaron utilizando el Cuestionario de Salud y Desempeño de la OMS. Se realizó un análisis de sensibilidad determinista. Resultados: El costo total estimado por paciente durante el primer año de tratamiento fue de 3,503.49 USD. La pérdida de productividad laboral fue el costo que más contribuyó a la carga económica (64.5%), seguido de los costos médicos directos (27.6%), mientras que los costos no médicos directos contribuyeron menos (7.9%). Se calculó una carga económica anual de poco más de 290 millones de dólares para los pacientes tratados en el sistema de salud privado similar a la CTSUNAM. El análisis de sensibilidad mostró que la prevalencia de insomnio crónico asociado a trastorno del estado de ánimo, la pérdida de productividad laboral y el porcentaje de personas que buscan atención en un sistema privado fueron los parámetros con mayor impacto sobre la estimación de la carga económica total. Conclusiones: Los costos del insomnio asociado a trastorno anímico son altos. Alteraciones de sueño y depresión en personas recuperadas de COVID-19 HA Suárez-Martínez,* AD Santana-Vargas,*,‡ L Juárez-Santiago,*,‡ G Millán-Rosas,*
s of the National Meeting of Sleep Medicine)十二大情绪障碍相关的慢性失眠的费用:在墨西哥GI Torres-Granados observacional的研究,* * JM Martínez-Núñez Barrera-Medina‡Cruz-Cruz C、F * L * U Jiménez-Correa,‡Carvalho-Silva López-Naranjo, * R Santana-Miranda‡*生物系统,红海边Xochimilco部;‡睡眠障碍诊所，UNAM。导言:尽管与COVID-19大流行相关的高患病率和全球发病率，但与情绪障碍相关的失眠相关成本仍然很少被研究。目的:确定与情绪障碍相关的失眠的直接和间接成本。材料和方法:这是一项前瞻性观察研究，包括2019年2月至2020年2月期间诊断为与情绪障碍(抑郁和/或焦虑)相关的慢性失眠的18 - 65岁患者。通过回顾医疗记录收集卫生资源使用数据。设计了一份问卷，以评估直接和间接非医疗成本，包括社会人口学数据、交通、能量饮料、体育活动支出、家庭装修、购买特殊配件、工作日和工资。采用世卫组织健康和绩效问卷确定缺勤和工作出勤情况。进行了确定性敏感性分析。结果:治疗第一年每位患者的总费用估计为3,503.49美元。劳动生产率的损失对经济负担的贡献最大(64.5%)，其次是直接医疗费用(27.6%)，而非直接医疗费用的贡献最小(7.9%)。据估计，在类似CTSUNAM的私人医疗系统中接受治疗的患者每年的经济负担略高于2.9亿美元。敏感性分析表明，与情绪障碍相关的慢性失眠的患病率、劳动生产率的损失和在私人系统中寻求护理的人的百分比是对总经济负担估计影响最大的参数。结论:与情绪障碍相关的失眠成本较高。COVID-19康复患者的睡眠障碍和抑郁HA suarez - martinez，* AD Santana-Vargas，*，‡L juarez - santiago，*，‡G millan - rosas，*
{"title":"Resúmenes de trabajos libres del XII Encuentro Nacional de Medicina del Dormir","authors":"Hidalgo – Tobon, García-Campos, Morón-Mendoza, Jiménez-Correa, Gutiérrez-Escobar, J. Azpiroz-Leehan, Santana-Miranda, J. Escobar-Alvarado, J. Sandoval-Zárate","doi":"10.35366/103459","DOIUrl":"https://doi.org/10.35366/103459","url":null,"abstract":"s of the XII National Meeting of Sleep Medicine Costos del insomnio crónico asociado a trastornos anímicos: un estudio observacional en México GI Torres-Granados,* JM Martínez-Núñez,* A Barrera-Medina,‡ C Cruz-Cruz,* U Jiménez-Correa,‡ L Carvalho-Silva,* F López-Naranjo,* R Santana-Miranda‡ *Departamento de Sistemas Biológicos, UAM Xochimilco; ‡Clínica de Trastornos del Sueño, UNAM. Introducción: Los costos relacionados con el insomnio asociado a trastornos del estado de ánimo siguen siendo poco estudiados pese a su alta prevalencia e incidencia mundial asociada a la pandemia COVID-19. Objetivos: Determinar los costos directos e indirectos del insomnio asociado a trastorno anímico. Material y métodos: Estudio observacional prospectivo, incluyó pacientes entre 18 y 65 años, diagnosticados con insomnio crónico asociado a trastornos del estado de ánimo (depresión y/o ansiedad) entre febrero de 2019 y febrero de 2020. Los datos sobre utilización de recursos sanitarios se recopilaron mediante la revisión de los registros médicos. Se diseñó un cuestionario para evaluar los costos no médicos directos e indirectos con datos sociodemográficos, transporte, bebidas energéticas, gastos en actividad física, modificaciones del hogar, compra de accesorios especiales, jornada laboral y salario. El ausentismo y el presentismo laboral se determinaron utilizando el Cuestionario de Salud y Desempeño de la OMS. Se realizó un análisis de sensibilidad determinista. Resultados: El costo total estimado por paciente durante el primer año de tratamiento fue de 3,503.49 USD. La pérdida de productividad laboral fue el costo que más contribuyó a la carga económica (64.5%), seguido de los costos médicos directos (27.6%), mientras que los costos no médicos directos contribuyeron menos (7.9%). Se calculó una carga económica anual de poco más de 290 millones de dólares para los pacientes tratados en el sistema de salud privado similar a la CTSUNAM. El análisis de sensibilidad mostró que la prevalencia de insomnio crónico asociado a trastorno del estado de ánimo, la pérdida de productividad laboral y el porcentaje de personas que buscan atención en un sistema privado fueron los parámetros con mayor impacto sobre la estimación de la carga económica total. Conclusiones: Los costos del insomnio asociado a trastorno anímico son altos. Alteraciones de sueño y depresión en personas recuperadas de COVID-19 HA Suárez-Martínez,* AD Santana-Vargas,*,‡ L Juárez-Santiago,*,‡ G Millán-Rosas,*","PeriodicalId":246416,"journal":{"name":"NCT Neumología y Cirugía de Tórax","volume":"186 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132401533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sebastián Campbell-Quintero, Santiago Campbell-Quintero, Santiago Campbell-Silva
{"title":"¿Es correcto el término ''neumomediastino espontáneo''?","authors":"Sebastián Campbell-Quintero, Santiago Campbell-Quintero, Santiago Campbell-Silva","doi":"10.35366/103460","DOIUrl":"https://doi.org/10.35366/103460","url":null,"abstract":"","PeriodicalId":246416,"journal":{"name":"NCT Neumología y Cirugía de Tórax","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122224016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"III Congreso de la Sociedad Latinoamericana de Fisiología Respiratoria (SOLAFIRE) 2019","authors":"Luis Torre-Bouscoulet","doi":"10.35366/NT192I","DOIUrl":"https://doi.org/10.35366/NT192I","url":null,"abstract":"","PeriodicalId":246416,"journal":{"name":"NCT Neumología y Cirugía de Tórax","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130173991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Demian Trueba Lozano, R. Villalobos, Víctor Flores Huerta, Adriana Hernández García, Edgar Meza Félix, Steve Arciniega Belmont, Juan Carlos Vázquez Minero
El quilotorax se define como la acumulacion de quilo en la cavidad pleural. La etiologia traumatica no iatrogenica ocurre en 0.2 a 3% de todos los casos. Presentamos el caso de un hombre de 18 anos de edad que ingreso con historial de agresion por terceras personas con instrumento punzocortante, la cual motivo toracotomia anterolateral derecha inicial para hemostasia de lesion pulmonar y rafia de lesion diafragmatica en el seno posterior paravertebral derecho. En el posoperatorio se documento gasto elevado a traves de sonda endopleural compatible con quilotorax, que se corroboro mediante citoquimico con trigliceridos de 243 mg/dl. Se intento manejo conservador con ayuno y nutricion parenteral; sin embargo, al quinto dia con estas medidas persistio con gasto superior a 1,000 cm3 e imagen radiografica con cavidad y acumulacion de liquido; por lo tanto, se llevo a cabo manejo quirurgico con pleurodesis. El paciente tuvo adecuada evolucion. Cinco dias despues inicio, dieta sin datos de nuevo quilotorax y se efectuo retiro de drenaje pleural y egreso al septimo dia
{"title":"Quilotórax traumático y su resolución quirúrgica, una entidad poco frecuente. A propósito de un caso","authors":"Demian Trueba Lozano, R. Villalobos, Víctor Flores Huerta, Adriana Hernández García, Edgar Meza Félix, Steve Arciniega Belmont, Juan Carlos Vázquez Minero","doi":"10.35366/NT192E","DOIUrl":"https://doi.org/10.35366/NT192E","url":null,"abstract":"El quilotorax se define como la acumulacion de quilo en la cavidad pleural. La etiologia traumatica no iatrogenica ocurre en 0.2 a 3% de todos los casos. Presentamos el caso de un hombre de 18 anos de edad que ingreso con historial de agresion por terceras personas con instrumento punzocortante, la cual motivo toracotomia anterolateral derecha inicial para hemostasia de lesion pulmonar y rafia de lesion diafragmatica en el seno posterior paravertebral derecho. En el posoperatorio se documento gasto elevado a traves de sonda endopleural compatible con quilotorax, que se corroboro mediante citoquimico con trigliceridos de 243 mg/dl. Se intento manejo conservador con ayuno y nutricion parenteral; sin embargo, al quinto dia con estas medidas persistio con gasto superior a 1,000 cm3 e imagen radiografica con cavidad y acumulacion de liquido; por lo tanto, se llevo a cabo manejo quirurgico con pleurodesis. El paciente tuvo adecuada evolucion. Cinco dias despues inicio, dieta sin datos de nuevo quilotorax y se efectuo retiro de drenaje pleural y egreso al septimo dia","PeriodicalId":246416,"journal":{"name":"NCT Neumología y Cirugía de Tórax","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124344845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G. Cantú-González, Fabiola N. Fernandez-Figueroa, Laura Gochicoa-Rangel, J. L. Miguel-Reyes, Claudia Vargas-Domínguez, R. Mejía-Alfaro, L. Torre-Bouscoulet
Measuring the fraction of exhaled nitric oxide makes it possible to quantify «in an indirect, quick and reliable» fashion, the magnitude of airway infl ammation in patients with respiratory diseases; especially in cases of asthma. Because of its simplicity, this technique has also become a useful tool for diagnosing, monitoring and evaluating the therapeutic compliance in patients with asthma, among other conditions. In addition, measuring fraction of exhaled nitric oxide can help prevent exacerbations because it allows increases in infl ammatory activity to be detected and treated immediately. The purpose of this document is to review practical aspects of the fraction of exhaled nitric oxide-measuring technique using a portable device, and to provide clinical physicians with useful instruments that will aid in achieving correct interpretations of results. We consider the fraction of exhaled nitric oxide-measuring technique to be an underutilized test in current respiratory medicine practice, so our motivation is to make practical, summarized information available to readers.
{"title":"Fracción exhalada de óxido nítrico. Recomendaciones clínicas y procedimiento","authors":"G. Cantú-González, Fabiola N. Fernandez-Figueroa, Laura Gochicoa-Rangel, J. L. Miguel-Reyes, Claudia Vargas-Domínguez, R. Mejía-Alfaro, L. Torre-Bouscoulet","doi":"10.35366/NTS192N","DOIUrl":"https://doi.org/10.35366/NTS192N","url":null,"abstract":"Measuring the fraction of exhaled nitric oxide makes it possible to quantify «in an indirect, quick and reliable» fashion, the magnitude of airway infl ammation in patients with respiratory diseases; especially in cases of asthma. Because of its simplicity, this technique has also become a useful tool for diagnosing, monitoring and evaluating the therapeutic compliance in patients with asthma, among other conditions. In addition, measuring fraction of exhaled nitric oxide can help prevent exacerbations because it allows increases in infl ammatory activity to be detected and treated immediately. The purpose of this document is to review practical aspects of the fraction of exhaled nitric oxide-measuring technique using a portable device, and to provide clinical physicians with useful instruments that will aid in achieving correct interpretations of results. We consider the fraction of exhaled nitric oxide-measuring technique to be an underutilized test in current respiratory medicine practice, so our motivation is to make practical, summarized information available to readers.","PeriodicalId":246416,"journal":{"name":"NCT Neumología y Cirugía de Tórax","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124425227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"COVID-19: ¿Qué pasa con el liderazgo?","authors":"Luis Torre-Bouscoulet","doi":"10.35366/111090","DOIUrl":"https://doi.org/10.35366/111090","url":null,"abstract":"","PeriodicalId":246416,"journal":{"name":"NCT Neumología y Cirugía de Tórax","volume":"54 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121551768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
José Carlos os Herrera-García, Ek Ixel Arellano-Montellano, Luis Enrique Jaramillo-Arellano, Andrea Espinoza Arellano
diagnóstico (SOAE) Material métodos: 5 pacientes diagnóstico síndrome aplicación mg ABSTRACT. Introduction: The binomial term overlap asthma/COPD is a subset of patients with persistence and airflow limitation that presents clinical features of both asthma and COPD. Initial studies have shown that omalizumab may be useful in patients with ACOS, it has been shown to improve symptoms, reduce exacerbations and hospitalization, as well as improve lung function parameters and reduced steroid requirement in these patients. Objective: To describe the effect of omalizumab in 5 patients with a diagnosis of overlying asthma/COPD syndrome (OAC) and administration of omalizumab. We describe the experience of our center and the benefits that the treatment has given to our patients. Material and methods: We present 5 cases of patients with a diagnosis of overlap asthma/COPD syndrome after application of omalizumab (300 mg SC each month) significantly improved their symptoms in ACT (asthma control test) and respiratory function tests, mainly in spirometry. This 5 patients gave their consent to present cases. Results: The 5 patients with OAC received Omalizumab have experienced improvement of symptoms in ACT (asthma control test) and improvement of 10 to 20 and 25 points. Omalizumab was well tolerated without complications. 100% of patients showed improvement in symptoms (ACT), higher percentage are women as described in the literature, patients tolerated the treatment without presenting major adverse effects. Conclusion: The cases described offer initial evidence of our medical practice on the benefits of omalizumab in patients with clinically improving overlying asthma/COPD syndrome. Omalizumab demonstrates good tolerance without presenting adverse effects. These benefits have allowed the patient a better quality of life and radically reduce their morbidity. words:
{"title":"Uso de omalizumab en cinco pacientes con síndrome de sobreposición asma-EPOC (SOAE) en un Hospital Universitario de Puebla: Un estudio observacional","authors":"José Carlos os Herrera-García, Ek Ixel Arellano-Montellano, Luis Enrique Jaramillo-Arellano, Andrea Espinoza Arellano","doi":"10.35366/NT191E","DOIUrl":"https://doi.org/10.35366/NT191E","url":null,"abstract":"diagnóstico (SOAE) Material métodos: 5 pacientes diagnóstico síndrome aplicación mg ABSTRACT. Introduction: The binomial term overlap asthma/COPD is a subset of patients with persistence and airflow limitation that presents clinical features of both asthma and COPD. Initial studies have shown that omalizumab may be useful in patients with ACOS, it has been shown to improve symptoms, reduce exacerbations and hospitalization, as well as improve lung function parameters and reduced steroid requirement in these patients. Objective: To describe the effect of omalizumab in 5 patients with a diagnosis of overlying asthma/COPD syndrome (OAC) and administration of omalizumab. We describe the experience of our center and the benefits that the treatment has given to our patients. Material and methods: We present 5 cases of patients with a diagnosis of overlap asthma/COPD syndrome after application of omalizumab (300 mg SC each month) significantly improved their symptoms in ACT (asthma control test) and respiratory function tests, mainly in spirometry. This 5 patients gave their consent to present cases. Results: The 5 patients with OAC received Omalizumab have experienced improvement of symptoms in ACT (asthma control test) and improvement of 10 to 20 and 25 points. Omalizumab was well tolerated without complications. 100% of patients showed improvement in symptoms (ACT), higher percentage are women as described in the literature, patients tolerated the treatment without presenting major adverse effects. Conclusion: The cases described offer initial evidence of our medical practice on the benefits of omalizumab in patients with clinically improving overlying asthma/COPD syndrome. Omalizumab demonstrates good tolerance without presenting adverse effects. These benefits have allowed the patient a better quality of life and radically reduce their morbidity. words:","PeriodicalId":246416,"journal":{"name":"NCT Neumología y Cirugía de Tórax","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124231930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F. Armas-Zárate, J. Morales-Gómez, Juan Carlos Vázquez-Minero, Edwin Gustavo Barrientos-Morales
{"title":"Perforación del tercio distal de la tráquea. A propósito de un caso","authors":"F. Armas-Zárate, J. Morales-Gómez, Juan Carlos Vázquez-Minero, Edwin Gustavo Barrientos-Morales","doi":"10.35366/111091","DOIUrl":"https://doi.org/10.35366/111091","url":null,"abstract":"","PeriodicalId":246416,"journal":{"name":"NCT Neumología y Cirugía de Tórax","volume":"169 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115750517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：